CRISPR is a gene-editing company that develops and commercializes gene-based medicines for the treatment of serious diseases.
Read moreAnnual Revenue
$903M
CRISPR's revenue is the ranked 1st among it's top 10 competitors. The top 10 competitors average 128.2M. Over the last four quarters, CRISPR's revenue has grown by 74.4%. Specifically, in Q1 2022's revenue was $ < 1M; in Q3 2021, it was $ < 1M; in Q2 2021, it was $900.7M; in Q1 2021, CRISPR's revenue was $ < 1M.